IP Library › Granted Patent US 12692314
Granted Patent B2
US 12692314 · App. 18/312,519 · Granted Jul 28, 2026

CD3/BCMA/CD38 trispecific antibodies

Inventors: Maria Pihlgren Bosch (La Chaux-de-Fonds, CH); Mario Perro (La Chaux-de-Fonds, CH); Olivia Hall (La Chaux-de-Fonds, CH); Laura Carretero Iglesia (La Chaux-de-Fonds, CH); Adam Drake (La Chaux-de-Fonds, CH); Daniela Pais (La Chaux-de-Fonds, CH); Rebecca Croasdale-Wood (La Chaux-de-Fonds, CH); Carole Estoppey (La Chaux-de-Fonds, CH); Michael Dyson (La Chaux-de-Fonds, CH); Thierry Monney (La Chaux-de-Fonds, CH)
Assignee: IGI THERAPEUTICS SA
C07K16/2809A61P35/00C07K16/2878C07K16/2896C07K2317/31C07K2317/515C07K2317/55C07K2317/565C07K2317/622C07K2317/70C07K2317/71C07K2317/72C07K2317/76C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12692314
App. No.
18/312,519
Granted
Jul 28, 2026
Kind
B2
Abstract

The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.

Claims (18)

1 . A trispecific antibody that binds to human CD3, human B-cell maturation antigen (BCMA), and human CD38, comprising:

a. a first heavy chain polypeptide, said first heavy chain polypeptide comprising

i. a first heavy chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 181, a CDR2 having the amino acid sequence shown as SEQ ID NO: 307, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 433, and

ii. a second heavy chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 234, a CDR2 having the amino acid sequence shown as SEQ ID NO: 360, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 486; and

b. a second heavy chain polypeptide, said second heavy chain polypeptide comprising a heavy chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 239, a CDR2 having the amino acid sequence shown as SEQ ID NO: 365, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 491; and

c. three light chain polypeptides, each of said light chain polypeptides comprising a light chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 721, a CDR2 having the amino acid sequence shown as SEQ ID NO: 722, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 723.

2 . The trispecific antibody of claim 1 , wherein the second heavy chain variable domain of the first heavy chain polypeptide is fused at the N-terminus to the C-terminus of the first heavy chain variable domain of the first heavy chain polypeptide via a peptide linker.

3 . The trispecific antibody of claim 1 , wherein said trispecific antibody comprises a non-naturally occurring Fc domain.

4 . The trispecific antibody of claim 1 , wherein one heavy chain polypeptide comprises a first engineered IgG1 CH3 domain and the other heavy chain polypeptide comprises a second engineered IgG1 CH3 domain, wherein said first engineered IgG1 CH3 domain comprises all of the substitutions of the group consisting of: Q347A, S364K, T366V, K370T, K392Y, F405S, Y407V, K409W, and T411 N according to EU numbering, and said second engineered IgG1 CH3 domain comprises all of the substitutions of the group consisting of: Q347E, Y349A, L351 F, S364T, T366V, K370T, T394D, V397L, D399E, F405A, Y407S, K409R, and T411R according to EU numbering.

5 . The trispecific antibody of claim 1 , wherein two of the three light chain polypeptides are covalently linked via disulfide bonding to the first heavy chain polypeptide and the third light chain polypeptide is covalently linked via disulfide bonding to the second heavy chain polypeptide.

6 . The trispecific antibody of claim 1 , wherein the first heavy chain polypeptide comprises a first heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 592.

7 . The trispecific antibody of claim 1 , wherein the first heavy chain polypeptide comprises a second heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 591.

8 . The trispecific antibody of claim 1 , wherein the second heavy chain polypeptide comprises a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 594.

9 . The trispecific antibody of claim 1 , wherein the first heavy chain polypeptide comprises a first heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 592, the first heavy chain polypeptide comprises a second heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 591, and the second heavy chain polypeptide comprises a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 594.

10 . A trispecific antibody that binds to human CD3, human BCMA, and human CD38, comprising:

(i) a first polypeptide comprising the amino acid sequence shown as SEQ ID NO: 546;

(ii) a second polypeptide comprising the amino acid sequence shown as SEQ ID NO: 547; and

(iii) a third, a fourth, and a fifth polypeptide each comprising the amino acid sequence shown as SEQ ID NO: 1.